Top Stories
The agreement will see the companies combine their resources to hunt for small-molecule drug candidates targeting oncology.
In conjunction with the move, nChroma Bio will undertake a restructuring, which news sources suggested will cut the biotech's workforce by around half.
Chief medical officer Eric Hughes will step down, to be replaced on an interim basis by David Gardiner, who heads innovative medicines and clinical development, until a permanent successor is found.
The agency will make a decision on sonesitatug vedotin in the second quarter of 2027.
Kesimpta is expected to generate $8 billion in peak sales, up from $6 billion previously, with estimates for both Scemblix and Leqvio raised from $4 billion to $5 billion.
Conference News
CELMoD programs advance across multiple myeloma and lymphoma, with Phase 3 readouts for ZENBEXUS™ (iberdomide) and mezigdomide, and Phase 2 data for golcadomideLandmark five-year TRANSFORM data demons...
Data Presented at the 2026 EORTC-NCI-AACR Symposium Show TROP2 Levels May Help Predict Which Tumors Respond to Reqorsa® and Modulating TROP2 May Enhance EfficacyAUSTIN, Texas, Nov. 19, 2026 /PRNewswir...
30% objective response rate and an 85% disease control rate on every 2-week (Q2W) schedule; all responses ongoing at data cut-offFavorable safety and tolerability profile with very few patients needin...
Results presented at American College of Rheumatology (ACR) Convergence shows positive data with a higher dose of mesenchymal stromal cells for refractory lupusWASHINGTON, Nov. 19, 2026 /PRNewswire/ -...
Presentations include late-breaking data demonstrating the potential of AI to inform breast cancer treatment decisionsCHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM) today announced that 16 a...



